Medicxi’s new €400M fund unites early, late stage investing

Medicxi’s newly closed third fund, its largest ever, will depart from the VC’s prior strategy by consolidating early and late stage investing into a single vehicle.

Medicxi III will deploy €400 million ($451.2 million) across all stages of development, from company creation through late-stage clinical assets that have already shown proof of concept. ...